The drug has been clinically proven in oncological therapy and treatment of pancreatitis in Japan (Kawase et al., 2012) and shown efficacy in vitro in combination with cathepsin inhibitors in SARS-CoV infected human HeLa cells expressing ACE2 and TMPRSS2. The gene discussed is TMPRSS2; the disease is pancreatitis.